On Dec 06, major Wall Street analysts update their ratings for $Edwards Lifesciences (EW.US)$, with price targets ranging from $75 to $90.
Goldman Sachs analyst David Roman maintains with a buy rating, and adjusts the target price from $80 to $90.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $88.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $75 to $78.
TD Cowen analyst Josh Jennings maintains with a hold rating, and maintains the target price at $75.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating, and sets the target price at $85.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
The outlook for Edwards Lifesciences appears increasingly positive following the company's analyst day and the introduction of new guidance. While the current valuation broadly mirrors expectations for Edwards' growth, continued adherence to this guidance could heighten investor interest, particularly leading up to moderate data revelations expected at TCT 2026.
Edwards Lifesciences presented its 2025 outlook and long-range plans during its Investor Day, addressing previous concerns about TAVR capacity issues and competitive pressures, which are anticipated to persist into 2025. Despite these challenges, the company's 2025 guidance excluding foreign exchange impacts was more optimistic than expected, projecting growth of 8%-10% compared to a consensus of 7.8%. This projection bolstered investor confidence, with analysts recognizing the company's solid positioning in attractive end-markets, multiple growth catalysts, and favorable valuation.
Following attendance at the annual Edwards Lifesciences analyst meeting, it was clear there is an emerging positive narrative for the company's future. The current market valuation of Edwards seems reasonable, pending further support from physician insights.
Edwards Lifesciences delivered a promising multiyear outlook during its annual investor day, reiterating its 2024 guidance and unveiling 2025 guidance that aligns with current market estimates.
Here are the latest investment ratings and price targets for $Edwards Lifesciences (EW.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間12月6日，多家華爾街大行更新了$愛德華生命科學 (EW.US)$的評級，目標價介於75美元至90美元。
高盛集團分析師David Roman維持買入評級，並將目標價從80美元上調至90美元。
巴克萊銀行分析師Matt Miksic維持買入評級，維持目標價88美元。
瑞士銀行分析師Danielle Antalffy維持持有評級，並將目標價從75美元上調至78美元。
TD Cowen分析師Josh Jennings維持持有評級，維持目標價75美元。
瑞穗證券分析師Anthony Petrone維持買入評級，目標價85美元。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
愛德華生命科學的前景在公司分析師日和新指引發布之後似乎越來越積極。雖然目前的估值大體反映了愛德華的增長預期，但持續遵循這一指引可能會增加投資者的興趣，特別是在TCt 2026預期的中等數據披露之前。
愛德華生命科學在其投資者日上介紹了2025年的前景和長期計劃，解決了關於TAVR產能問題和競爭壓力的先前擔憂，這些問題預計將持續到2025年。儘管面臨這些挑戰，該公司在不考慮匯率期貨影響的情況下，2025年的指引比預期更爲樂觀，預計增長8%-10%，而共識爲7.8%。這一預測增強了投資者信心，分析師認識到該公司在具有吸引力的最終市場中的穩固定位、多重增長催化劑和有利估值。
在參加年度愛德華生命科學分析師會議後，很明顯公司未來正在出現積極的敘述。愛德華當前的市場估值似乎合理，期待進一步的醫生見解作爲支持。
愛德華生命科學在其年度投資者日上提供了令人鼓舞的多年度前景，重申了2024年的指引，並揭示了與當前市場估算相符的2025年指引。
以下爲今日8位分析師對$愛德華生命科學 (EW.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
